AstraZeneca (AZN): news on Tuesday 13 October 2026

The 23 stories

Each headline's own score, strongest first. Links go to the publisher.

• −9.2 AstraZeneca’s efzimfotase alfa fails in adult and adolescent HPP trial The Pharma Letter
  Drug failed in adult and adolescent HPP trial.
• +9.2 Positive clinical profile of AstraZeneca’s tozorakimab in COPD The Pharma Letter
  Positive clinical profile for tozorakimab in COPD.
• +8.3 AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi Proactive financial news
  Citi sees $4.4bn peak sales potential.
• −8.3 AstraZeneca’s HICKORY Trial Fails Primary Endpoint Due to Design Mismatch azat.tv
  Trial failed primary endpoint, though framed as design issue.
• +7.5 AstraZeneca opens new global strategic R&D centre in US PMLiVE
  New global strategic R&D centre opened in US.
• +6.7 Why is AstraZeneca stock up today? Summit $2B funding and GBX12,030 resistance test Traders Union
  Stock up on Summit funding.
• −5.8 AstraZeneca pins bone disease drug’s Phase III failure on high placebo response Clinical Trials Arena
  Phase III failure blamed on high placebo response.
• +5.8 Citi sees AstraZeneca's rare disease drug efzim... Pluang
  Citi sees potential in the rare disease drug.
• +5.0 SOPHiA GENETICS, Myriad Genetics and AstraZeneca Collaborate to Advance Precision Oncology in Prostate Cancer BioPharma APAC
  Collaboration advancing precision oncology in prostate cancer.
• −5.0 AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint Yahoo Finance
  Missed key Phase III endpoint but some gains shown.
• +5.0 Carterra and AstraZeneca collaborate on AI-driven drug discovery Manufacturing Chemist
  AI-driven drug discovery collaboration.
• +5.0 Why Is AstraZeneca (LSE:AZN) Stock In Focus After Its Summit Therapeutics Deal This Week? Kalkine Media
  Summit deal puts stock in focus.
• +5.0 How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo Yahoo Finance
  Tagrisso combination NDA filing by partner supports AstraZeneca's drug.
• +4.2 AstraZeneca completes Summit investment and AstraZeneca stock trades at EUR 142.63 - ad-hoc-news.de ad-hoc-news.de
  Completed Summit investment.
• +4.2 AstraZeneca, Hi-Precision team up to advance digital pathology in PH Manila Standard
  Digital pathology partnership in the Philippines.
• −3.3 AstraZeneca sheds more light on efzimfotase alfa's earlier Phase III miss in hypophosphatasia FirstWord Pharma
  Further detail on earlier Phase III miss.
• +3.3 Summit Therapeutics (SMMT) Teams With AstraZeneca And Daiichi As Valuation Debate Heats Up Simply Wall Street
  Summit teaming with AstraZeneca, valuation debate around partner.
• −2.5 AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal Benzinga
  Improvements seen despite missing key trial goal.
• −1.7 AstraZeneca reports 17.05-meter HICKORY result: stock after-hours at EUR 142.20 - ad-hoc-news.de ad-hoc-news.de
  Trial result with minor share price dip after hours.
• +0.8 AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting - Slideshow (NYSE:AZN) 2026-10-12 Seeking Alpha
  Conference presentation, largely routine.
• 0.0 AstraZeneca at ASBMR 2026: rare disease push hinges on new bone drug Investing.com UK
  Rare disease strategy depends on bone drug, mixed outlook.
• 0.0 AstraZeneca stock pre-market at EUR 142.73 - ad-hoc-news.de ad-hoc-news.de
  Routine pre-market price quote, no real news.
• 0.0 AstraZeneca stock trades at EUR 142.83 with a GBP 187.3 billion market value - ad-hoc-news.de ad-hoc-news.de
  Routine share price and market value update.